Dermavant submits sNDA for tapinarof cream, 1% to treat AD in patients 2 years and up


The sNDA submission follows additional positive topline data that was presented in Janurary 2024, highlighting an open-label, long-term extension study evaluating tapinarof cream, 1%.

Tapinarof cream, 1% sNDA filed to treat atopic dermatitis in patients 2 years and up | Image Credit: © John Doe - © John Doe -

Tapinarof cream, 1% sNDA filed to treat atopic dermatitis in patients 2 years and up | Image Credit: © Araki Illustrations - © Araki Illustrations -

Tapinarof cream, 1% (VTAMA; Dermavant Sciences) to treat atopic dermatitis (AD) in adult and children 2 years and older has taken another step forward in the FDA process.1

Dermavant announced in a press release that it has submitted a supplemental New Drug Application (sNDA) to the federal agency for the topical, once-daily, steroid-free aryl hydrocarbon receptor agonist.1

Treatment is intended for both acute and long-term management of AD, which impacts approximately 16.5 million adults and over 9.6 million children in the United States.1

The sNDA submission is supported by positive data from a pair of identical double-blind, randomized, vehicle-controlled phase 3 trials, ADORING 1 (NCT05014568) and ADORING 2 (NCT05032859). Supportive data also comes from an interim analysis of the ADORING 3 phase 3 trial (NCT05142774), a 48-week, open-label, long-term extension study.1

In ADORING 1 and ADORING 2, tapinarof cream 1% achieved statistically significant improvement compared to vehicle in the Validated Investigator Global Assessment for AD (vIGA-AD) scores of 0 or 1 (clear or almost clear) with at least a 2-grade improvement from baseline at week 8 (primary outcome).1

"Greater reductions in the Peak Pruritus-Numeric Rating Scale (PP-NRS) mean scores for [tapinarof] cream versus vehicle were observed as early as Day 1 in ADORING 1 (-1.2 vs -0.9), 24 hours after first application, and Day 2 in ADORING 2 (-1.6 vs -1.4)," said Eric Simpson, MD, MCR, professor, Frances J. Storrs Medical Dermatology, director, CLEAR Eczema Center, Oregon Health & Science University, in a prior interview with Contemporary Pediatrics.2

"Itch remains the most burdensome and prevalent symptoms of [AD], and these results highlight the potential of tapinarof as a clinically meaningful therapy with the ability to reduce itch for adults and children living with ]AD]," added Simpson.2

Click here for detailed results from the ADORING 1 and ADORING 2 trials, along with additional commentary from Eric Simposon, MD, MCR.

Dermavant states more than 85% of people with AD experience itching daily, and over 67% of patients with AD reported this itch has altered sleep patterns in the past week.1 Over half of children with AD reported that sleep disturbance is one of the most bothersome symptoms of AD.1

In a December 2023 video interview with Contemporary Pediatrics, Lawrence Eichenfield, MD, professor of dermatology and pediatrics, vice chair, Department of Dermatology, chief, Pediatric and Adolescent Dermatology, University of California, San Diego, and Rady Children’s Hospital, San Diego, California, discussed topical steroid and non-steroidal treatments for pediatric AD, and discussed tapinarof cream 1% as a potential exciting treatment.3

"[Tapinarof] is a whole different mechanism of action," Eichenfield said. "[Dermavant] completed their pediatric studies with that 1% cream down to children age 2 with really really good datasets and can be very, very exciting and that drug's become very popular for psoriasis in adults."3

Click here to watch the full video interview.

Tapinarof cream, 1% was approved by the FDA to treat plaque psoriasis in adults on May 24, 2022.1

In the ADORING phase 3 program, data indicated no new safety or tolerability signals of concern in the 2 years and older patient population, and adverse events were "mostly mild to moderate with a low study discontinuation rate due to adverse events," Dermavant stated in the press release.1

According to Dermavant, the most common adverse reactions (≥ 1%) in individuals treated with tapinarof cream, 1% were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.1


1. Dermavant submits supplemental New Drug Application (sNDA) to FDA for VTAMA (tapinarof) cream, 1% for the treatment of atopic dermatitis in adults and children 2 years of age and older. Dermavant Sciences. Press release. February 14, 2024. Accessed February 14, 2024.

2. Fitch, J. Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD. Contemporary Pediatrics. October 13, 2024. Accessed February 14, 2024.

3. Fitch, J. Topical steroid and non-steroidal treatments for pediatric atopic dermatitis and potential new agents. Contemporary Pediatrics. December 12, 2024. Accessed February 14, 2024.

Related Videos
Juanita Mora, MD
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
Rupa Wong, MD | Image Credit: Rupa Wong, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
John Bradley, MD
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx -
Related Content
© 2024 MJH Life Sciences

All rights reserved.